Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 15/01/2025

    Similarities discovered between vascular calcification and bone growth

    University of Tübingen research team observes biochemical process in living cells – indications of new approach to preventing heart attacks and strokes

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/similarities-discovered-between-vascular-calcification-and-bone-growth
  • Press release - 13/01/2025

    New tool for synthetic biology

    Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of "DNA origami". The system they developed may facilitate the transportation of large therapeutic loads into cells. This opens up a new way for the targeted administration of medication and other therapeutic interventions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-tool-synthetic-biology
  • Press release - 07/01/2025

    Researchers have a better understanding of how our cells dispose of waste while developing ways to control it

    A research team from Freiburg and Frankfurt has discovered how cells recognise and internally break down waste. The results are relevant for the development of therapies for diseases such as Alzheimer’s.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-have-better-understanding-how-our-cells-dispose-waste-while-developing-ways-control-it
  • Press release - 03/01/2025

    New approaches against metastatic breast cancer: mini-tumors from circulating cancer cells

    Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-against-metastatic-breast-cancer-mini-tumors-circulating-cancer-cells
  • Press release - 19/12/2024

    Antibody that neutralizes inhibitory factors involved in nerve regeneration leads to enhanced motor function after acute spinal cord injury

    Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December 2024.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-neutralizes-inhibitory-factors-involved-nerve-regeneration-leads-enhanced-motor-function-after-acute-spinal-cord-injury
  • Press release - 11/12/2024

    Top German research prize goes to Freiburg cancer researcher

    The Gottfried Wilhelm Leibniz-Prize 2025 goes to Prof. Dr Robert Zeiser for his outstanding research in haematology and immunology. Zeiser’s research at the University of Freiburg and the Medical Center – University of Freiburg have led, among other things, to new types of cancer therapy that has increased survival rates and the patients’ quality of life.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/top-german-research-prize-goes-freiburg-cancer-researcher
  • Transcranial magnetic stimulation (TMS) - 10/12/2024 Laughing person with EEG on their head lying on a medical couch.

    sync2brain: using magnetic waves to combat depression

    In cases where standard therapies for mental illnesses such as depression prove ineffective, transcranial magnetic stimulation (TMS) offers a promising alternative. This method uses magnetic pulses to stimulate specific regions of the brain. The company sync2brain has developed a system that leverages EEG measurements to tailor stimulation to each patient's unique brain wave patterns, that may significantly enhance the therapy's…

    https://www.gesundheitsindustrie-bw.de/en/article/news/sync2brain-using-magnetic-waves-combat-depression
  • Press release - 09/12/2024

    Brain tumour cells rapidly integrate into brain-wide neuronal circuits

    Researchers at the Medical Faculty of Heidelberg University and the Heidelberg University Hospital have used modified rabies viruses to label glioblastoma tumour cells and their direct cell contacts in the mouse brain. The new method showed that the tumour cells are connected to different types of nerve cells throughout the entire brain at a very early stage of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-tumour-cells-rapidly-integrate-brain-wide-neuronal-circuits
  • NMI spin-off develops theranostics - 02/12/2024 Before immunotherapy weak ICE-T signals in the tumour in blue and green, after immunotherapy strong signals in red and pink.

    immuneAdvice develops diagnostics to predict the efficacy of immunotherapies

    Certain types of cancer are already being effectively treated using immunotherapies, though success rates can vary significantly between patients. Researchers from the Natural and Medical Sciences Institute (NMI) in Reutlingen, along with colleagues at the University of Tübingen, are working on a diagnostic approach to accompany therapy, which would rapidly assess whether the treatment is effective or requires adjustment.

    https://www.gesundheitsindustrie-bw.de/en/article/news/immuneadvice-develops-diagnostics-predict-efficacy-immunotherapies
  • Vicinity Bio: Optimisation of cancer diagnostics - 27/11/2024 Das Bild zeigt eine mikroskopische Aufnahme eines Gewebes. Die Aufnahme ist bunt und unterschiedliche Zelltypen lassen sich deutlich erkennen.

    Comprehensive histological diagnostics through high-dimensional imaging and artificial intelligence

    Microscopic examination of tissue samples is essential, particularly in tumour diagnostics. The Tübingen-based company Vicinity Bio leverages cutting-edge imaging technologies combined with machine learning to generate comprehensive datasets of individual cells from tissue sections. This approach not only helps identify more targeted therapies but also enhances our understanding of cellular functions and processes within tissues and tumours.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Comprehensive-histological-diagnostics-through-high-dimensional-imaging-and-artificial-intelligence
  • Press release - 25/11/2024

    Chromosomal chaos promotes therapy resistance in leukemia cells and opens up new treatment approaches

    Chromosomal instability plays a role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/chromosomal-chaos-promotes-therapy-resistance-leukemia-cells-and-opens-new-treatment-approaches
  • Press release - 15/11/2024

    Selenium proteins as a possible new target for cancer research

    An important enzyme helps the body produce selenium proteins – this discovery could open up new strategies for treating cancer in children. This has been published by scientists from the University of Würzburg, the University Sao Paolo, the German Cancer Research Center (DKFZ) and the Heidelberg Stem Cell Institute HI-STEM*.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/selenium-proteins-possible-new-target-cancer-research
  • Press release - 15/11/2024

    Patient association raises 10,000 euros for work on PURA syndrome - Donation for research into rare neuronal developmental disorder at Ulm University

    PURA syndrome is a rare developmental disorder of the brain for which there is currently no cure. The patient association PURA Syndrome Germany was founded last year. Since then, the affected families have been collecting donations with great dedication – and have decided to donate the majority of this money to research into the syndrome at Ulm University.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/patient-association-raises-10000-euros-work-pura-syndrome-donation-research-rare-neuronal-developmental-disorder-ulm-university
  • Press release - 14/11/2024

    Novel method for fighting tumors

    Making existing cancer therapy more efficient while significantly reducing the side effects on healthy tissue - this is the aim of a project at Aalen University. It is being funded with one million euros from the Carl Zeiss Foundation. The biophysicist and his team are developing innovative nanoparticles made of gold. The particles use radiotherapy and chemotherapy simultaneously and kill the cancer cells in a targeted manner.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-method-for-fighting-tumors
  • Press release - 05/11/2024

    Heidelberg scientist receives highly endowed EC synergy grant

    Heidelberg scientist Dr Venera Weinhardt has received an ERC Synergy Grant for a pioneering biomedical research project. The European Research Council (ERC) is granting this funding to advance soft X-ray microscopy. This imaging technique along with other innovations will be used to investigate the hepatitis E virus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-scientist-receives-highly-endowed-ec-synergy-grant
  • Press release - 30/10/2024

    Diabetes switch in DNA: Non-coding region in the genome influences ONECUT1 gene

    They are underestimated genetic control elements: it is known that changes in the genome can trigger diabetes. But now researchers at the University Hospital Ulm and the INSERM Cochin Institute in Paris have shown that a previously under-researched region of the genome also plays a crucial role in the development of this disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/diabetes-switch-dna-non-coding-region-genome-influences-onecut1-gene
  • Press release - 09/10/2024

    Language model "UroBot“ surpasses the accuracy of experienced urologists

    Scientists at the German Cancer Research Center (DKFZ), together with doctors from the Urological Clinic of the Mannheim University Hospital, have developed and successfully tested a chatbot based on artificial intelligence. "UroBot" was able to answer questions from the urology specialist examination with a high degree of accuracy, surpassing both other language models and the accuracy of experienced urologists.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/language-model-urobot-surpasses-accuracy-experienced-urologists
  • Chronic inflammatory bowel diseases - 25/09/2024 Vor schwarzem Hintergrund sind kugelförmige Zellansammlungen zu sehen.

    Proinflammatory regulatory T lymphocytes as a therapeutic target in Crohn's disease

    Chronic inflammatory bowel diseases are very stressful for those affected and increase the risk of bowel cancer. PD Dr. Robyn Laura Kosinsky from the Bosch Health Campus in Stuttgart, together with researchers from the USA, identified disfunctional regulatory T cells as important drivers of inflammation in Crohn's disease. They also found that with the help of an epigenetically active drug, it was possible to restore the cells’ original…

    https://www.gesundheitsindustrie-bw.de/en/article/news/proinflammatory-regulatory-t-lymphocytes-therapeutic-target-crohns-disease
  • Press release - 19/09/2024

    Quality standards for looking into the tumor genome

    Personalized medicine with individually tailored therapies is becoming more a reality in cancer. This requires a look into the genetic material of tumors, a molecular diagnostic tumor profile. A research group from the German Network for Personalized Medicine (DNPM) has recorded the quality standards according to which genome analyses are carried out in Germany. The data is a prerequisite for integrating gene sequencing into routine care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-standards-looking-tumor-genome
  • Press release - 26/08/2024

    Synthetic Immunology: Approaching a Turning Point in the Treatment and Prevention of Disease

    Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/synthetic-immunology-approaching-turning-point-treatment-and-prevention-disease
  • Press release - 22/08/2024

    Validated targets for personalized cancer immunotherapy

    Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/validated-targets-personalized-cancer-immunotherapy
  • Press release - 14/08/2024

    New vaccine against cervical cancer combines prophylactic and therapeutic activities

    Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-vaccine-against-cervical-cancer-combines-prophylactic-and-therapeutic-activities
  • Press release - 01/08/2024

    Targeted therapy for cancer of unknown primary (Cup)

    Encouraging results from a large international study led by Heidelberg have recently been published in the journal “Lancet”: The genetic material of cancer cells with unknown tissue of origin contains numerous targets for specific drugs that are already available and have been developed to treat other forms of cancer. These suppressed the disease in CUP patients for significantly longer than chemotherapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeted-therapy-cancer-unknown-primary-cup
  • Press release - 10/07/2024

    HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

    HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-raises-euro-15-million-series-c-round-advance-clinical-development-hrx-215-liver-regeneration
  • TWYCE GmbH - 10/07/2024 A micrograph shows how two T cells attack two tumour cells.

    Better immune response against prostate cancer thanks to new bispecific antibodies

    TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies

Page 2 / 10

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search